Jane Street’s UroGen Pharma URGN Stock Holding History

Jane Street’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$423K	Sell	23,500 -37,100	-61%	-$744K	﹤0.01%	8440
2025 Q4	$1.42M	Sell	60,600 -34,700	-36%	-$753K	﹤0.01%	5425
2025 Q3	$1.9M	Sell	95,300 -13,400	-12%	-$241K	﹤0.01%	5033
2025 Q2	$1.49M	Buy	+108,700	New	+$1.04M	﹤0.01%	4914
2024 Q3	–	Sell	-21,400	Closed	-$359K	–	10429
2024 Q2	$359K	Buy	+21,400	New	+$304K	﹤0.01%	7512
2020 Q4	–	Sell	-25,000	Closed	-$482K	–	8138
2020 Q3	$482K	Hold	25,000	–	–	﹤0.01%	5210
2020 Q2	$653K	Buy	+25,000	New	+$611K	﹤0.01%	4673

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Jane Street's URGN Position: Q4 2025 in Review

Jane Street sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 328,419 shares — an estimated $7.12M sold.

Jane Street first reported a position in URGN in Q2 2018 and held it in 16 quarters. The position peaked at $6.55M in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

Jane Street reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
Jane Street sold 328,419 UroGen Pharma shares in Q4 2025, an estimated $7.12M.
Jane Street first reported a position in UroGen Pharma in Q2 2018 and held it in 16 quarters.
Jane Street's UroGen Pharma position peaked at $6.55M in Q3 2025.
167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.